KOĀTE® [Antihemophilic Factor (Human)]

IMPORTANT CO-PAY INFORMATION

Eligibility Guidelines:

To be eligible for co-pay assistance up to $15,000 annually, patients must:

- Be prescribed KOĀTE for the treatment of hemophilia A.
- Be commercially insured.
- Express financial need.

Restrictions:

- Not valid for prescriptions eligible for reimbursement by any federal or state healthcare programs, such as:
  - Medicare
  - Medicaid
  - Medigap
  - Veterans Affairs
  - Department of Defense
  - Tricare
  - Any other federal or state-funded programs
- Claims must be received within 30 days of dispense date.

For medical benefits only, EOBs must also be submitted within 90 days of the claim submission date.

EOBs = Explanation of Benefits

Enrollment Registration for Medical Benefits Claims:

For patients covered under **medical benefits**, the process is as easy as 1-2-3:

1. Scan the QR code to open the Medmonk KOĀTE Co-pay Assistance Program portal at https://koate.medmonk.com.
2. If you are new to Medmonk, use the **Provider Registration** link to register your pharmacy for instant adjudication.
3. Use the **Provider Login** to begin the patient enrollment and eligibility check.

KOĀTE, Antihemophilic Factor (Human)
INDICATION
KOĀTE is a human plasma derived anti-hemophilic factor indicated for the control and prevention of bleeding episodes or in order to perform emergency and elective surgery in patients with hemophilia A (hereditary Factor VIII deficiency). KOĀTE is not indicated for the treatment of von Willebrand disease.

IMPORTANT SAFETY INFORMATION
- KOĀTE is contraindicated in patients who have had hypersensitivity reactions including anaphylaxis, to KOĀTE or its components. If hypersensitivity symptoms occur, discontinue use of the product immediately and administer appropriate emergency treatment

Please see Full Prescribing Information at www.mykoate.com.

Enrollment Registration for Pharmacy Benefits Claims:

For patients covered under pharmacy benefits, the claim must be billed to Medmonk as a secondary payer:

BIN: 016664 | **PCN:** MEDMONK | **Cardholder ID:** MEDMONK

KOĀTE® [Antihemophilic Factor (Human)]

Please contact Kedrion Connects™ with additional questions.

Kedrion Connects™ Support Services:

Phone: 888-262-8040 | Fax: 408-419-1768

Contact Kedrion Biopharma

Kedrion Biopharma Commercial Rare Disease Team

Jamie Mattern, National Rare Disease Sales Director
Email: j.mattern@kedrion.com
Cell: 609-464-1295

Patricia Underland, Clinical Nurse Educator
Email: p.underland@kedrion.com
Cell: 201-401-0918

Mindy Eldridge, Clinical Nurse Educator
Email: m.eldridge@kedrion.com
Cell: 913-608-6504

Kedrion Biopharma Customer Service

Website:

Phone: 855-353-7466

Fax: 855-751-7951

Email: kedrioncs@icsconnect.com

Hours: Monday–Friday
7:00 a.m.–7:00 p.m. CT

IMPORTANT SAFETY INFORMATION, continued

- The formation of neutralizing antibodies (inhibitors) to FVIII may occur. If expected plasma FVIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor VIII inhibitor concentration.
- Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B or AB blood groups who are receiving large or frequent doses.
- KOĀTE is made from human plasma and, therefore, carries a risk of transmitting infectious agents, such as viruses, the agent of the variant Creutzfeldt-Jakob disease (vCJD), or unknown infectious agents.
- The most common adverse drug reactions (frequency > 5% of subjects) observed in the clinical trial were nervousness, headache, abdominal pain, nausea, paresthesia and blurred vision. **To report SUSPECTED ADVERSE REACTIONS contact Kedrion Biopharma at 1-855-353-7466.**

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/MedWatch, or call 1-800-FDA-1088

Please see Full Prescribing Information at www.mykoate.com.

Kedrion Biopharma